HLS Therapeutics (HLS) News Today → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free HLS Stock Alerts C$3.72 -0.28 (-7.00%) (As of 05/30/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 12:41 AM | marketbeat.comHLS Therapeutics (TSE:HLS) Shares Down 7% HLS Therapeutics (TSE:HLS) Stock Price Down 7%May 28, 2024 | finance.yahoo.comNew Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine TreatmentMay 10, 2024 | marketbeat.comRaymond James Lowers HLS Therapeutics (TSE:HLS) Price Target to C$4.00Raymond James reduced their price objective on shares of HLS Therapeutics from C$5.00 to C$4.00 in a research note on Friday.May 9, 2024 | morningstar.comHLS Therapeutics Inc HLSMay 9, 2024 | finance.yahoo.comHLS Therapeutics Announces Q1 2024 Financial ResultsApril 9, 2024 | finance.yahoo.comHLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 8, 2024 | finance.yahoo.comNew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsMarch 18, 2024 | marketbeat.comHLS Therapeutics (TSE:HLS) PT Lowered to C$5.00 at Raymond JamesRaymond James lowered their price objective on HLS Therapeutics from C$6.50 to C$5.00 in a report on Monday.March 17, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57March 15, 2024 | marketbeat.comStifel Nicolaus Trims HLS Therapeutics (TSE:HLS) Target Price to C$4.15Stifel Nicolaus cut their price objective on HLS Therapeutics from C$4.35 to C$4.15 in a research report on Friday.March 14, 2024 | finance.yahoo.comHLS Therapeutics Inc. (TSE:HLS) stock most popular amongst retail investors who own 40%, while hedge funds hold 39%March 14, 2024 | finance.yahoo.comHLS Therapeutics Announces Fiscal 2023 Financial ResultsMarch 13, 2024 | markets.businessinsider.comHLS Therapeutics earnings: here's what to expectFebruary 21, 2024 | finance.yahoo.comSeveral Insiders Invested In HLS Therapeutics Flagging Positive NewsFebruary 9, 2024 | marketbeat.comHLS Therapeutics Inc. (TSE:HLS) Expected to Post FY2023 Earnings of ($0.93) Per ShareHLS Therapeutics Inc. (TSE:HLS - Free Report) - Clarus Securities issued their FY2023 earnings per share (EPS) estimates for shares of HLS Therapeutics in a report issued on Tuesday, February 6th. Clarus Securities analyst G. Ulybyshev expects that the company will post earnings of ($0.93) per shFebruary 9, 2024 | marketbeat.comHLS Therapeutics' (HLS) "Buy" Rating Reiterated at Clarus SecuritiesClarus Securities reaffirmed a "buy" rating on shares of HLS Therapeutics in a research note on Tuesday.February 6, 2024 | ca.finance.yahoo.comStocks in play: HLS Therapeutics Inc.February 6, 2024 | finance.yahoo.comHLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug PlanDecember 20, 2023 | msn.comPharma breakthroughs: 10 novel drug approvals that made headlines in 2023December 18, 2023 | marketwatch.comHLS Therapeutics CFO Tim Hendrickson to Step DownDecember 18, 2023 | msn.comHLS Therapeutics appoints John Hanna as interim CFODecember 18, 2023 | finance.yahoo.comHLS Therapeutics Announces CFO DepartureDecember 11, 2023 | msn.com2 Top Pharmaceutical Stocks to Buy on the TSX TodayNovember 15, 2023 | finance.yahoo.comSome HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's EstimatesNovember 14, 2023 | finance.yahoo.comNew REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at BaselineNovember 9, 2023 | marketwatch.comHLS Therapeutics Plans to Buyback Up to 5% of Its SharesNovember 9, 2023 | finance.yahoo.comHLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer BidNovember 9, 2023 | markets.businessinsider.comHLS Therapeutics earnings preview: what Wall Street is expectingOctober 2, 2023 | finance.yahoo.comEmergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of DirectorsSeptember 7, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy HLS Therapeutics StockAugust 26, 2023 | seekingalpha.comHLTRF HLS Therapeutics Inc.August 23, 2023 | theglobeandmail.comHLS Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (HLS)August 13, 2023 | markets.businessinsider.comBloom Burton Remains a Buy on HLS Therapeutics Inc (HLS)August 11, 2023 | marketbeat.comHLS Therapeutics (TSE:HLS) Issues Earnings ResultsHLS Therapeutics (TSE:HLS - Get Free Report) issued its quarterly earnings data on Thursday. The company reported C($0.39) EPS for the quarter, missing analysts' consensus estimates of C($0.17) by C($0.22). HLS Therapeutics had a negative return on equity of 18.55% and a negative net margin of 41.79%. During the same quarter in the prior year, the business posted ($0.36) EPS.August 11, 2023 | marketbeat.comHLS Therapeutics (TSE:HLS) Price Target Cut to C$15.00Stifel Nicolaus reduced their price objective on shares of HLS Therapeutics from C$18.00 to C$15.00 in a research report on Friday.August 3, 2023 | finance.yahoo.comHLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference CallAugust 3, 2023 | msn.comHLS Therapeutics (HLTRF) Price Target Decreased by 12.21% to 11.36July 28, 2023 | markets.businessinsider.comHLS Therapeutics Inc (HLS) Gets a Hold Rating from Raymond JamesJuly 28, 2023 | marketbeat.comRaymond James Trims HLS Therapeutics (TSE:HLS) Target Price to C$9.00Raymond James cut their price target on HLS Therapeutics from C$10.00 to C$9.00 and set a "market perform" rating for the company in a report on Friday.July 28, 2023 | finance.yahoo.comWith 38% ownership, HLS Therapeutics Inc. (TSE:HLS) has piqued the interest of hedge funds investorsJuly 10, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Buy on HLS Therapeutics Inc (HLS)July 6, 2023 | fool.comHls Therapeutics (TSX: HLS)July 1, 2023 | finance.yahoo.comAthyrium Capital Announces Sale of Shares of HLS TherapeuticsJune 22, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on HLS Therapeutics Inc (HLS)June 22, 2023 | marketwatch.comHLS Therapeutics Names John Welborn Chairman, Adds Polar Asset Management Candidate to BoardJune 22, 2023 | finance.yahoo.comHLS Therapeutics Announces Updates to its Board of DirectorsJune 19, 2023 | markets.businessinsider.comHLS Therapeutics Inc (HLS) Received its Third Buy in a RowJune 8, 2023 | finance.yahoo.comHLS Therapeutics Announces Agreement with Polar Asset Management Partners and Retirement of Two Directors from the Board of DirectorsJune 8, 2023 | markets.businessinsider.comStifel Nicolaus Thinks HLS Therapeutics Inc’s Stock is Going to RecoverMay 25, 2023 | baystreet.caThis Healthcare Stock Just Hit a 52-Week Low: Is it Time to Buy? Get HLS Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. HLS Media Mentions By Week HLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HLS News Sentiment▼1.790.81▲Average Medical News Sentiment HLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HLS Articles This Week▼20▲HLS Articles Average Week Get HLS Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aurora Cannabis News Today Organigram News Today Cardiol Therapeutics News Today Cipher Pharmaceuticals News Today BioSyent News Today Decibel Cannabis News Today Charlotte's Web News Today MediPharm Labs News Today Medicure News Today Indiva News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:HLS) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryUnlock Explosive Gains with This Defense StockBehind the MarketsElon’s Revenge on BidenTradeSmithClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin Pro Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
